He established mouse cancer models (such as breast, prostate, colon, lung, and liver cancer and metastasis), developed multiple immunochemical and immunofluorescence staining methods for tumor biomarker studies, and used DNA-damaging agents, in combination with Chk1 inhibitors, to evaluate the potential therapeutic effect of drugs in vivo.

His research interest is the development of cancer models for preclinical translational studies. He has established several human-in-mouse tumor lines. Currently, he is using orthotropic PDX mouse models of human TNBC to determine the therapeutic effect of Chk1 and PARP inhibitors, in combination with several DNA-damaging agents, on breast cancer with different p53 and PARP statuses.